COMPANY

TEGA Therapeutics

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $498K (SBIR Phase I 1R43HL184653-01, new, notice Sep 17, 2026). NIH RePORTER 1R43HL184653-01 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 1R43HL184653-01
  Organization: TEGA THERAPEUTICS, INC.; City/State: LA JOLLA, CA; Project number: 1R43HL184653-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 498086; Administering IC: National Heart Lung and Blood Institute; Project title: Activities and Biophysical Properties of Heparins, Engineered to Reduce HIT; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 17, 2026 Grant Government grant — SBIR: $498,086 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
Aug 6, 2025 Grant Government grant — SBIR: $500,000 (annual award, as published), announced Aug 6, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Last 2 years.

Sep 17, 2026 Government grant — SBIR: $498,086 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
Aug 6, 2025 Government grant — SBIR: $500,000 (annual award, as published), announced Aug 6, 2025. Agency: NIH/NINDS. Source: government award database. source ↗